IMR Press / CEOG / Volume 42 / Issue 6 / DOI: 10.12891/ceog2006.2015

Clinical and Experimental Obstetrics & Gynecology (CEOG) is published by IMR Press from Volume 47 Issue 1 (2020). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Original Research
Analysis of the use of cyclosporin A to treat refractory immune recurrent spontaneous abortion
Show Less
1 Department of Obstetrics, Shandong Weifang People's Hospital, Weifang (China)
Clin. Exp. Obstet. Gynecol. 2015, 42(6), 739–742; https://doi.org/10.12891/ceog2006.2015
Published: 10 December 2015
Abstract

Purpose: This study aims to determine the curative effect of cyclosporin A (CsA) in treating refractory immune recurrent spontaneous abortion (RSA). Patients with recurrent abortion caused by dysimmunity were enrolled. Materials and Methods: The patients were given aspirin, prednisone, heparin, immunotherapy with their husband’s leukomonocyte, and intravenous immunoglobulin (IVIG) treatment, but treatment outcomes were unsuccessful. Therefore, CsA was added to treat the women before and after pregnancy. During treatment, CsA concentration was maintained at 80 ng/ml to 150 ng/ml. The clinical effect and pregnancy outcome were observed. Results: Of the 26 patients, 20 cooperated and accomplished complete pregnancy. Twelve cases showed hypertensive disorders during pregnancy but did not exhibit symptoms of preeclampsia. Three cases were lost to follow-up. The success rate was 76.92%. Twenty patients underwent premature labor (34 weeks to 37 weeks). Nevertheless, the mothers and their children were all healthy. Conclusion: An appropriate dose of CsA has good curative effects and pregnancy results in the treatment of RSA.
Keywords
Cyclosporine
Recurrent spontaneous abortion
Pregnancy
Share
Back to top